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It has been shown that individuals with inherited
predisposition to cancer (including colon, breast and
ovary) have increased sensitivity to bleomycin. We
published that bleomycin-induced chromosomal
instability in BRCA1 carriers is inhibited by selenium
supplementation in physiologic (according to WHO)
doses. Selenium was shown to reduce the risk of several
cancers. 
The aim of our study is to verify the idea that
selenium supplementation of diet reduces the risk of
cancer in women with a BRCA1 mutation. We
performed two pilot studies involving 200 healthy
BRCA1 mutation carriers (100 matched pairs – cases
and controls). After two years of oral selenium
administration the frequency of BRCA1-associated
tumours was two times lower in women who
supplemented their diet with selenium, as compared
to women without supplementation. 
We decided to verify these results in a clinical trial
of a large series of BRAC1 positive women. This project
includes 1,800 BRCA1 carriers aged older than 25,
healthy or after unilateral mastectomy because of breast
cancer. All women supplement their diet with selenium
solution (Sel Vita Gen) produced by Vifarm S.A. in
Warsaw. Fourteen centres throughout Poland
participated in this study. Until December 2005 the
study included 1,469 women with the BRCA1 mutation.
Now, 960 women have regular supplementation with
Sel Vita Gen and these are seen every 6 months for
control visits (clinical examination and analysis of serum
selenium level). 509 do not have supplementation
because of pregnancy, bad toleration, or withdrawal
of their participation. 
After 18 months of this study we reported 8 new
cases of cancer in healthy women (5 breast cancers,
2 ovarian duct cancers, 1 ovarian cancer) and 8
cancer cases in women after mastectomy (5 breast
cancers, 3 ovarian cancers). In order to obtain reliable
results we will continue this study until we diagnose at
least 60 new cases of cancer. 
